Gastric Variceal Hemorrhage: Risk Factors for Hemorrhagic Recurrence after Biological Glue Injection
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S418
DOI: 10.1055/s-0044-1783747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von M. Mabrouk und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Identify risk factors associated with recurrent GV(gastric varices ) bleeding at 6 weeks following biologic glue injection and evaluate its impact on mortality.
Methods
This retrospective analytical study included hospitalized patients at the Hepato-Gastroenterology department of Monastir between January 2014 and October 2023 with exclusive upper digestive bleeding due to GV rupture and who underwent oesophagogastroduodenoscopy with endoscopic hemostasis using biologic glue. Clinical, biological, and endoscopic data related to different GV bleeding episodes were recorded. GV were classified according to the Sarin classification. Cirrhosis was considered advanced for a Child score>B7. Decompensation of cirrhosis (excluding PHT-related bleeding) was defined by clinical ascites, hepatic encephalopathy≥grade II. Hepatic mortality was attributed to bleeding, decompensated cirrhosis, or infection. Cox regression was used for multivariate analysis and risk estimation Results In a study of 33 patients experiencing 75 episodes of gastric variceal (GV) bleeding, the mean age was 58 years. Cirrhosis was the main cause of portal hypertension (PHT) in 72.7% of cases, often in advanced stages. Most episodes involved oesophageal varices and hypertensive gastropathy, with some occurrences during antithrombotic therapy. Red blood cell transfusions and biologic glue injections were common treatments. Over a follow-up period averaging 363 days, half the patients experienced GV bleeding recurrence within a median of 345 days, resulting in a 6-week recurrence rate of 18.7%. At the 6-week mark, recurrence was linked to advanced cirrhosis, concurrent liver decompensation, active bleeding during endoscopy, specific types of varices, and hypertensive gastropathy. However, factors like age, sex, underlying PHT cause, and treatment specifics did not impact GV recurrence. Hypertensive gastropathy was the sole independent predictor of recurrence during follow-up. Hepatic mortality stood at 42.4% within a median of 35 weeks and was closely related to GV bleeding recurrence. Multivariate analysis highlighted GV recurrence and diabetes as predictors of mortality.
Conclusions
GV bleeding recurrence at 6 weeks appears linked to hepatic disease severity, HG presence, and active bleeding during endoscopy. This recurrence, particularly in diabetic patients, is associated with increased short- and medium-term hepatic mortality. Therefore, closer and more vigilant monitoring is advisable for these high-risk patients." Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Mabrouk, M., Azer, G., Mehdi, A., Jemni, I., Chaabane, N. B., & Safer, L. (2024). Gastric Variceal Hemorrhage: Risk Factors for Hemorrhagic Recurrence after Biological Glue Injection. Endoscopy, 56(S 02 S 02), S418. https://doi.org/10.1055/s-0044-1783747
Vancouver
Mabrouk M, Azer G, Mehdi A, Jemni I, Chaabane NB, Safer L. Gastric Variceal Hemorrhage: Risk Factors for Hemorrhagic Recurrence after Biological Glue Injection. Endoscopy. 2024;56(S 02 S 02):S418. doi:10.1055/s-0044-1783747
BibTeX
@article{Mabrouk2024,
author = {Mabrouk, M. and Azer, G. and Mehdi, A. and Jemni, I. and Chaabane, N. Ben and Safer, L.},
title = {Gastric Variceal Hemorrhage: Risk Factors for Hemorrhagic Recurrence after Biological Glue Injection},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S418},
doi = {10.1055/s-0044-1783747}
}
EUVIMED